title: Plasmodium falciparum and Plasmodium vivax genotypes and efficacy of intermittent preventive treatment in Papua New Guinea.
abstract: Intermittent preventive treatment of infants (IPTi) reduces early childhood malaria-related morbidity. While genotypic drug resistance markers have proven useful in predicting the efficacy of antimalarial drugs in case management, there are few equivalent data relating to their protective efficacy when used as IPTi. The present data from an IPTi trial in Papua New Guinea demonstrate how these markers can predict protective efficacy of IPTi for both Plasmodium falciparum and Plasmodium vivax.
authors.affiliation: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea Infection and Immunity Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia Department of Medical Biology, University of Melbourne, Parkville, Australia barnadas@wehi.edu.au ivomueller@fastmail.fm.
authors.forename: Celine
authors.initials: C
authors.lastname: Barnadas
authors.affiliation: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea Swiss Tropical and Public Health Institute, Basel, Switzerland.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Senn
authors.affiliation: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea.
authors.forename: Jonah
authors.initials: J
authors.lastname: Iga
authors.affiliation: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea.
authors.forename: Lincoln
authors.initials: L
authors.lastname: Timinao
authors.affiliation: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea.
authors.forename: Sarah
authors.initials: S
authors.lastname: Javati
authors.affiliation: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea Infection and Immunity Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia.
authors.forename: Elisheba
authors.initials: E
authors.lastname: Malau
authors.affiliation: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea.
authors.forename: Patricia
authors.initials: P
authors.lastname: Rarau
authors.affiliation: Burnet Institute, Melbourne, Australia.
authors.forename: John C
authors.initials: JC
authors.lastname: Reeder
authors.affiliation: Vector Borne Diseases Unit, Papua New Guinea Institute of Medical Research (PNGIMR), Goroka, Papua New Guinea.
authors.forename: Peter
authors.initials: P
authors.lastname: Siba
authors.affiliation: Infection and Immunity Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia Department of Medical Biology, University of Melbourne, Parkville, Australia.
authors.forename: Harin
authors.initials: H
authors.lastname: Karunajeewa
authors.affiliation: Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USA.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Zimmerman
authors.affiliation: School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Davis
authors.affiliation: Infection and Immunity Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia Department of Medical Biology, University of Melbourne, Parkville, Australia Centre de Recerca en Salut Internacional de Barcelona, Barcelona, Spain barnadas@wehi.edu.au ivomueller@fastmail.fm.
authors.forename: Ivo
authors.initials: I
authors.lastname: Mueller
mesh_terms: D000962:Antimalarials / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004094:Dihydropteroate Synthase / Q000235:genetics; D004338:Drug Combinations; D004351:Drug Resistance / Q000235:genetics*; D005819:Genetic Markers / Q000235:genetics; D005838:Genotype; D006801:Humans; D007223:Infant; D016778:Malaria, Falciparum / Q000188:drug therapy / Q000469:parasitology / Q000517:prevention & control; D016780:Malaria, Vivax / Q000188:drug therapy / Q000469:parasitology / Q000517:prevention & control; D026901:Membrane Transport Proteins / Q000235:genetics; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics; D010219:Papua New Guinea; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D010966:Plasmodium vivax / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D015800:Protozoan Proteins / Q000235:genetics; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics
chemical_list: D000962:Antimalarials; D004094:Dihydropteroate Synthase; D004338:Drug Combinations; D005819:Genetic Markers; D026901:Membrane Transport Proteins; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D015800:Protozoan Proteins; D013762:Tetrahydrofolate Dehydrogenase; C513498:Mdr1 protein, Plasmodium falciparum; C416369:PfCRT protein, Plasmodium falciparum